Related Experiment Video
Updated: May 16, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Sodium butyrate attenuates liver fibrogenesis via promoting H4K8 crotonylation
Ruiqi Tang1, Hua Zha1, Rongrong Liu2
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou, 310003, China.
Abstract:
Sodium butyrate (NaB), a histone deacetylase (HDAC) inhibitor derived from dietary sources, demonstrates its potential in improving liver fibrosis in mice. This study explored NaB's impact on liver fibrosis through histone crotonylation. In vitro, NaB significantly inhibited the growth of TGF-β-stimulated LX2 hepatic stellate cells and reduced the expression of fibrotic markers ACTA2, the encoding gene of αSMA, and COL1A1 proportionally to the dosage. In vivo, NaB treatment of CCl4-induced ICR mice led to notable gains in liver function and a marked suppression in liver fibrosis. NaB inhibited Hdac2 and Hdac3 expression leading to increased H4K8 crotonylation, and modulated key fibrosis-related genes, providing a mechanistic basis for its therapeutic potential. Trichostatin A (TSA) exhibited similar effects to NaB, supporting the importance of HDAC inhibition in modulating these pathways. Overall, NaB's modulation of HDAC activity and histone crotonylation reveals a novel mechanism underlying its impact on liver fibrosis, highlighting its promise as a treatment for liver disease.
Insights
Sodium butyrate (NaB), a histone deacetylase inhibitor, shows promise for treating liver fibrosis. It improves liver function and reduces fibrosis by altering histone crotonylation, offering a novel therapeutic approach.
Area of Science:
- Biochemistry
- Hepatology
- Molecular Biology
Background:
- Liver fibrosis is a significant health concern.
- Histone deacetylase (HDAC) inhibitors are being explored for therapeutic potential.
- Dietary compounds like sodium butyrate (NaB) offer a unique avenue for investigation.
Purpose of the Study:
- To investigate the therapeutic potential of sodium butyrate (NaB) in liver fibrosis.
- To elucidate the mechanism of NaB's action through histone crotonylation.
- To evaluate NaB's effects both in vitro and in vivo.
Main Methods:
- In vitro studies using TGF-β-stimulated LX2 hepatic stellate cells.
- In vivo studies using CCl4-induced liver fibrosis model in ICR mice.
- Analysis of fibrotic markers, HDAC expression, and histone crotonylation (H4K8).
Main Results:
- NaB inhibited LX2 cell growth and reduced fibrotic markers (ACTA2, COL1A1) dose-dependently.
- NaB treatment improved liver function and suppressed fibrosis in mice.
- NaB inhibited Hdac2/Hdac3, increasing H4K8 crotonylation and modulating fibrosis-related genes.
Conclusions:
- Sodium butyrate (NaB) demonstrates significant efficacy in ameliorating liver fibrosis.
- NaB's mechanism involves HDAC inhibition and increased histone crotonylation.
- NaB presents a promising therapeutic strategy for liver disease treatment.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:12Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue
Published on: May 5, 2022
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Feedback Inhibition
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Co-activators and Co-repressors